PURPOSE: We aimed to determine whether low-risk breast masses can be effectively managed with unenhanced magnetic resonance imaging (MRI) combining T2-weighted sequences with diffusion-weighted imaging (DWI) instead of immediate biopsy to decrease negative biopsy rates. METHODS: After institutional review board and patient approvals, 141 consecutive women with 156 low-risk breast masses, who underwent unenhanced MRI and later on received a final diagnosis, were included in the study. There were 72 BI-RADS 3 masses in women with relative risk factors and 84 BI-RADS 4A masses, all referred for biopsy. Apparent diffusion coefficient (ADC) cutoff was 0.90×10-3 mm2/s. According to ADC values and T2-weighted imaging characteristics, masses were classified as either malignant or benign. Unenhanced MRI results were compared with final diagnoses obtained by histopathology or imaging surveillance, and diagnostic values were calculated. RESULTS: Of 156 masses, 112 underwent biopsy. Four malignancies were diagnosed, three of which having ADC values lower than the cutoff. In women who rejected the biopsy, masses were stable during a follow-up of at least two years (n=44). MRI revealed 91% specificity and 99% negative predictive value (NPV) for detection of breast cancer. CONCLUSION: Combination of T2-weighted imaging with DWI is a feasible method to further characterize breast masses with a low probability of malignancy. With the use of unenhanced MRI instead of immediate biopsy, it might be possible to decrease negative biopsy rates of low-risk breast masses.
PURPOSE: We aimed to determine whether low-risk breast masses can be effectively managed with unenhanced magnetic resonance imaging (MRI) combining T2-weighted sequences with diffusion-weighted imaging (DWI) instead of immediate biopsy to decrease negative biopsy rates. METHODS: After institutional review board and patient approvals, 141 consecutive women with 156 low-risk breast masses, who underwent unenhanced MRI and later on received a final diagnosis, were included in the study. There were 72 BI-RADS 3 masses in women with relative risk factors and 84 BI-RADS 4A masses, all referred for biopsy. Apparent diffusion coefficient (ADC) cutoff was 0.90×10-3 mm2/s. According to ADC values and T2-weighted imaging characteristics, masses were classified as either malignant or benign. Unenhanced MRI results were compared with final diagnoses obtained by histopathology or imaging surveillance, and diagnostic values were calculated. RESULTS: Of 156 masses, 112 underwent biopsy. Four malignancies were diagnosed, three of which having ADC values lower than the cutoff. In women who rejected the biopsy, masses were stable during a follow-up of at least two years (n=44). MRI revealed 91% specificity and 99% negative predictive value (NPV) for detection of breast cancer. CONCLUSION: Combination of T2-weighted imaging with DWI is a feasible method to further characterize breast masses with a low probability of malignancy. With the use of unenhanced MRI instead of immediate biopsy, it might be possible to decrease negative biopsy rates of low-risk breast masses.
Authors: Rubina M Trimboli; Nicola Verardi; Francesco Cartia; Luca A Carbonaro; Francesco Sardanelli Journal: AJR Am J Roentgenol Date: 2014-09 Impact factor: 3.959
Authors: Janet K Baum; Lucy G Hanna; Suddhasatta Acharyya; Mary C Mahoney; Emily F Conant; Lawrence W Bassett; Etta D Pisano Journal: Radiology Date: 2011-04-18 Impact factor: 11.105
Authors: Sana Parsian; Habib Rahbar; Kimberly H Allison; Wendy B Demartini; Matthew L Olson; Constance D Lehman; Savannah C Partridge Journal: Radiology Date: 2012-10-02 Impact factor: 11.105
Authors: Wenchi Liang; William F Lawrence; Caroline B Burnett; Yi-Ting Hwang; Matthew Freedman; Bruce J Trock; Jeanne S Mandelblatt; Marc E Lippman Journal: Breast Cancer Res Treat Date: 2003-05 Impact factor: 4.872
Authors: Catherine S Giess; Lisa Zorn Smeglin; Jack E Meyer; Julie A Ritner; Robyn L Birdwell Journal: J Ultrasound Med Date: 2012-12 Impact factor: 2.153
Authors: Sebastian Wojcinski; Esther Boehme; André Farrokh; Philipp Soergel; Friedrich Degenhardt; Peter Hillemanns Journal: BMC Cancer Date: 2013-03-27 Impact factor: 4.430
Authors: Katja Pinker; Linda Moy; Elizabeth J Sutton; Ritse M Mann; Michael Weber; Sunitha B Thakur; Maxine S Jochelson; Zsuzsanna Bago-Horvath; Elizabeth A Morris; Pascal At Baltzer; Thomas H Helbich Journal: Invest Radiol Date: 2018-10 Impact factor: 6.016
Authors: Sebastian Bickelhaupt; Jana Tesdorff; Frederik Bernd Laun; Tristan Anselm Kuder; Wolfgang Lederer; Susanne Teiner; Klaus Maier-Hein; Heidi Daniel; Anne Stieber; Stefan Delorme; Heinz-Peter Schlemmer Journal: Eur Radiol Date: 2016-05-18 Impact factor: 5.315
Authors: Sebastian Bickelhaupt; Franziska Steudle; Daniel Paech; Anna Mlynarska; Tristan Anselm Kuder; Wolfgang Lederer; Heidi Daniel; Martin Freitag; Stefan Delorme; Heinz-Peter Schlemmer; Frederik Bernd Laun Journal: PLoS One Date: 2017-04-28 Impact factor: 3.240
Authors: Jinchao Feng; Junqing Xu; Shudong Jiang; Hong Yin; Yan Zhao; Jiang Gui; Ke Wang; Xiuhua Lv; Fang Ren; Brian W Pogue; Keith D Paulsen Journal: Breast Cancer Res Date: 2017-10-24 Impact factor: 6.466